As we know, EML4-ALK fusion and EGFR mutation are often exclusive for most patients, and incidence rate of overlapping EML4-ALK fusion and EGFR sensitive mutation was only about 0–8 % in NSCLC patients [5, 22]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.